公开(公告)号：US20150126508A1

公开(公告)日：2015-05-07

申请号：US14400508

申请日：2013-04-02

Applicant: EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY

Inventor： Honglin Li ,  Yufang Xu ,  Zhenjiang Zhao ,  Xiaofeng Liu ,  Wei Zhou ,  Fang Bai ,  Mengzhu Xue ,  Lei Zhang ,  Youli Zhang

IPC: C07D475/00

CPC classification number: C07D475/00 ,  C07D239/50

Abstract: Provided are a pteridine ketone derivative used as an EGFR, BLK, and FLT3 inhibitor and applications thereof. Specifically, provided are a compound of the following formula I, a pharmaceutical composition containing the compound of the formula I, and use of compound in preparing medicine for treating diseases mediated by EGFR, BLK, or FLT3 or inhibiting EGFR, BLK, and FLT3.

Abstract translation: 提供用作EGFR，BLK和FLT3抑制剂的蝶啶酮衍生物及其应用。 具体地，提供下式I的化合物，含有式I化合物的药物组合物，以及化合物在制备用于治疗由EGFR，BLK或FLT3介导的疾病或抑制EGFR，BLK和FLT3的疾病的药物中的用途。

公开(公告)号：US09670213B2

公开(公告)日：2017-06-06

申请号：US14400508

申请日：2013-04-02

Applicant: EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY

Inventor： Honglin Li ,  Yufang Xu ,  Zhenjiang Zhao ,  Xiaofeng Liu ,  Wei Zhou ,  Fang Bai ,  Mengzhu Xue ,  Lei Zhang ,  Youli Zhang

IPC: C07D401/12 ,  C07D475/04 ,  C07D487/02 ,  C07D475/00 ,  C07D239/50

CPC classification number: C07D475/00 ,  C07D239/50

Abstract: Provided are a pteridine ketone derivative used as an EGFR, BLK, and FLT3 inhibitor and applications thereof. Specifically, provided are a compound of the following formula I, a pharmaceutical composition containing the compound of the formula I, and use of compound in preparing medicine for treating diseases mediated by EGFR, BLK, or FLT3 or inhibiting EGFR, BLK, and FLT3.

公开(公告)号：US11306095B2

公开(公告)日：2022-04-19

申请号：US15577518

申请日：2016-05-30

Applicant: EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY

Inventor： Honglin Li ,  Yufang Xu ,  Zhenjiang Zhao ,  Wei Zhou ,  Yuqiong Xu ,  Deheng Sun ,  Xia Wang ,  Zhuo Chen

IPC: C07D487/04 ,  A61P35/00 ,  A61P35/02 ,  A61K31/519 ,  C07D475/00

Abstract: The present invention relates to a pteridinone derivative serving as an EGFR inhibitor and use thereof. Specifically, the present invention relates to a compound represented by the following formula I, pharmaceutical composition comprising the compound of the following formula I, and use of the compound in preparation of drugs for treating EGFR-mediated diseases or inhibiting EGFR.